Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.

Currier MA, Sprague L, Rizvi TA, Nartker B, Chen CY, Wang PY, Hutzen BJ, Franczek MR, Patel AV, Chaney KE, Streby KA, Ecsedy JA, Conner J, Ratner N, Cripe TP.

Oncotarget. 2017 Mar 14;8(11):17412-17427. doi: 10.18632/oncotarget.14885.

2.

Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.

Kurokawa C, Geekiyanage H, Allen C, Iankov I, Schroeder M, Carlson B, Bakken K, Sarkaria J, Ecsedy JA, D'Assoro A, Friday B, Galanis E.

J Neurooncol. 2017 Jan;131(1):41-48. doi: 10.1007/s11060-016-2285-8. Epub 2016 Nov 5.

3.

Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.

Venkatakrishnan K, Ecsedy JA.

Clin Pharmacol Ther. 2017 Jan;101(1):99-113. doi: 10.1002/cpt.544. Epub 2016 Nov 25. Review.

PMID:
27804123
4.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG.

Oncotarget. 2016 Aug 2;7(31):50290-50301. doi: 10.18632/oncotarget.10366.

5.

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.

Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A.

J Natl Cancer Inst. 2015 Dec 30;108(6):djv406. doi: 10.1093/jnci/djv406. Print 2016 Jun.

6.

Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer.

Niu H, Manfredi M, Ecsedy JA.

Front Oncol. 2015 Aug 24;5:189. doi: 10.3389/fonc.2015.00189. eCollection 2015. Review.

7.

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.

Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A.

Clin Cancer Res. 2015 Dec 1;21(23):5338-48. doi: 10.1158/1078-0432.CCR-15-0293. Epub 2015 Jul 7.

8.

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.

Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG.

Front Pharmacol. 2015 Jun 16;6:120. doi: 10.3389/fphar.2015.00120. eCollection 2015.

9.

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.

Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J, Janowick DA, Kadambi VJ, LeRoy PJ, Stirling M, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Balani SK, Bolen JB, Manfredi MG, Claiborne CF.

ACS Med Chem Lett. 2015 Apr 22;6(6):630-4. doi: 10.1021/ml500409n. eCollection 2015 Jun 11.

10.

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A.

Cancer Res. 2015 Jan 1;75(1):181-93. doi: 10.1158/0008-5472.CAN-14-2405. Epub 2014 Nov 14.

11.

Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.

Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, Lehman NL.

Cancer Res. 2014 Oct 1;74(19):5364-70. doi: 10.1158/0008-5472.CAN-14-0386. Epub 2014 Aug 8.

12.

Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).

Huck JJ, Zhang M, Mettetal J, Chakravarty A, Venkatakrishnan K, Zhou X, Kleinfield R, Hyer ML, Kannan K, Shinde V, Dorner A, Manfredi MG, Shyu WC, Ecsedy JA.

Mol Cancer Ther. 2014 Sep;13(9):2170-83. doi: 10.1158/1535-7163.MCT-14-0027. Epub 2014 Jun 30.

13.

The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.

Hong X, O'Donnell JP, Salazar CR, Van Brocklyn JR, Barnett KD, Pearl DK, deCarvalho AC, Ecsedy JA, Brown SL, Mikkelsen T, Lehman NL.

Cancer Chemother Pharmacol. 2014 May;73(5):983-90. doi: 10.1007/s00280-014-2430-z. Epub 2014 Mar 14.

14.

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Iyer SP.

Invest New Drugs. 2014 Jun;32(3):489-99. doi: 10.1007/s10637-013-0050-9. Epub 2013 Dec 20.

15.

Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.

Neel NF, Stratford JK, Shinde V, Ecsedy JA, Martin TD, Der CJ, Yeh JJ.

Mol Cancer Ther. 2014 Jan;13(1):122-33. doi: 10.1158/1535-7163.MCT-12-1232. Epub 2013 Nov 12.

16.

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.

Palani S, Patel M, Huck J, Zhang M, Balani SK, Yang J, Chen S, Mettetal J, Manfredi M, Shyu WC, Ecsedy JA, Chakravarty A.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1255-64. doi: 10.1007/s00280-013-2305-8. Epub 2013 Oct 8.

PMID:
24101146
17.

The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE.

Clin Cancer Res. 2013 Apr 1;19(7):1717-28. doi: 10.1158/1078-0432.CCR-12-2383. Epub 2013 Feb 12.

18.

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC.

Oncogene. 2014 Jan 30;33(5):539-49. doi: 10.1038/onc.2012.632. Epub 2013 Jan 21.

19.

Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.

Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A.

EMBO Mol Med. 2013 Jan;5(1):149-66. doi: 10.1002/emmm.201201378. Epub 2012 Nov 25.

20.

Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N.

Clin Cancer Res. 2012 Sep 15;18(18):5020-30. doi: 10.1158/1078-0432.CCR-12-1072. Epub 2012 Jul 18.

21.

Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.

Muscal JA, Scorsone KA, Zhang L, Ecsedy JA, Berg SL.

Invest New Drugs. 2013 Feb;31(1):39-45. doi: 10.1007/s10637-012-9831-9. Epub 2012 Jun 6.

22.

Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Lehman NL, O'Donnell JP, Whiteley LJ, Stapp RT, Lehman TD, Roszka KM, Schultz LR, Williams CJ, Mikkelsen T, Brown SL, Ecsedy JA, Poisson LM.

Cell Cycle. 2012 Feb 1;11(3):489-502. doi: 10.4161/cc.11.3.18996. Epub 2012 Feb 1.

23.

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.

Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB.

Clin Cancer Res. 2011 Dec 15;17(24):7614-24. doi: 10.1158/1078-0432.CCR-11-1536. Epub 2011 Oct 20.

24.

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, ONeil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA.

Cancer Res. 2011 Feb 1;71(3):675-85. doi: 10.1158/0008-5472.CAN-10-1030. Epub 2010 Dec 10.

25.

The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents.

Wysong DR, Chakravarty A, Hoar K, Ecsedy JA.

Cell Cycle. 2009 Mar 15;8(6):876-88. Epub 2009 Mar 21.

PMID:
19221504
26.

A high-throughput liposome substrate assay with automated lipid extraction process for PI 3-kinase.

Lingaraj T, Donovan J, Li Z, Li P, Doucette A, Harrison S, Ecsedy JA, Dang L, Zhang W.

J Biomol Screen. 2008 Oct;13(9):906-11. doi: 10.1177/1087057108324498. Epub 2008 Sep 23.

PMID:
18812570
27.

Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.

LeRoy PJ, Hunter JJ, Hoar KM, Burke KE, Shinde V, Ruan J, Bowman D, Galvin K, Ecsedy JA.

Cancer Res. 2007 Jun 1;67(11):5362-70.

28.

MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy.

Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, Ecsedy JA.

Mol Cell Biol. 2007 Jun;27(12):4513-25. Epub 2007 Apr 16.

29.

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11. Epub 2007 Feb 23.

30.
31.

Expression of mouse sialic acid on gangliosides of a human glioma grown as a xenograft in SCID mice.

Ecsedy JA, Holthaus KA, Yohe HC, Seyfried TN.

J Neurochem. 1999 Jul;73(1):254-9.

32.

Tumor-infiltrating macrophages influence the glycosphingolipid composition of murine brain tumors.

Ecsedy JA, Yohe HC, Bergeron AJ, Seyfried TN.

J Lipid Res. 1998 Nov;39(11):2218-27.

33.

Ganglioside composition of a mouse brain tumor grown in the severe combined immunodeficiency (SCID) mouse.

Seyfried TN, el-Abbadi M, Ecsedy JA, Griffin ME, Yohe HC.

Mol Chem Neuropathol. 1998 Jan;33(1):27-37.

PMID:
9493174
34.

Ganglioside biosynthetic gene expression in experimental mouse brain tumors.

Ecsedy JA, Manfredi MG, Yohe HC, Seyfried TN.

Cancer Res. 1997 Apr 15;57(8):1580-3.

35.

Influence of host cell infiltration on the glycolipid content of mouse brain tumors.

Seyfried TN, el-Abbadi M, Ecsedy JA, Bai HW, Yohe HC.

J Neurochem. 1996 May;66(5):2026-33.

PMID:
8780032

Supplemental Content

Loading ...
Support Center